The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC

…, A Kacen, M Alon, AT Ręgo, E Stacher-Priehse… - Nature cancer, 2023 - nature.com
Immunotherapy revolutionized treatment options in cancer, yet the mechanisms underlying
resistance in many patients remain poorly understood. Cellular proteasomes have been …

Distribution and prognostic significance of gluconeogenesis and glycolysis in lung cancer

E Smolle, P Leko, E StacherPriehse, L Brcic… - Molecular …, 2020 - Wiley Online Library
Inhibition of glycolysis has been considered as a therapeutic approach in aggressive cancers
including lung cancer. Abbreviated gluconeogenesis, mediated by phosphoenolpyruvate …

[HTML][HTML] Inhibiting eicosanoid degradation exerts antifibrotic effects in a pulmonary fibrosis mouse model and human tissue

…, D Zabini, S Trautmann, E Stacher-Priehse… - Journal of Allergy and …, 2020 - Elsevier
Background Idiopathic pulmonary fibrosis (IPF) is a disease with high 5-year mortality and
few therapeutic options. Prostaglandin (PG) E 2 exhibits antifibrotic properties and is reduced …

[HTML][HTML] IL-1 receptor blockade skews inflammation towards Th2 in a mouse model of systemic sclerosis

…, A Sahu-Osen, E Stacher-Priehse… - European …, 2019 - Eur Respiratory Soc
The interleukin (IL)-1 family of cytokines is strongly associated with systemic sclerosis (SSc)
and pulmonary involvement, but the molecular mechanisms are poorly understood. The aim …

Resident cell lineages are preserved in pulmonary vascular remodeling

…, W Klepetko, E StacherPriehse… - The Journal of …, 2018 - Wiley Online Library
Pulmonary vascular remodeling is the main pathological hallmark of pulmonary hypertension
disease. We undertook a comprehensive and multilevel approach to investigate the origin …

[HTML][HTML] Influence of eukaryotic translation initiation factor 6 on non–small cell lung cancer development and progression

…, F Gollowitsch, E Stacher-Priehse… - European Journal of …, 2018 - Elsevier
Non–small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide.
Dysregulation of protein synthesis plays a major role in carcinogenesis, a process …

[HTML][HTML] Phospholipid dynamics in ex vivo lung cancer and normal lung explants

J Lesko, A Triebl, E Stacher-Priehse… - … & Molecular Medicine, 2021 - nature.com
In cancer cells, metabolic pathways are reprogrammed to promote cell proliferation and
growth. While the rewiring of central biosynthetic pathways is being extensively studied, the …

[HTML][HTML] Bronchoscopic probe-based confocal laser endomicroscopy to diagnose diffuse parenchymal lung diseases

E Silbernagel, E Stacher-Priehse, J Dinkel… - … Vasculitis, and Diffuse …, 2022 - ncbi.nlm.nih.gov
Background: Diagnosis of diffuse parenchymal lung disease (DPLD) is based on clinical
evaluation, radiological imaging and histology. However, additional techniques are warranted …

Predicting Long-term Survival After Lung Metastasectomy in Patients With Malignant Germ-cell Tumors

…, G Stathopoulos, E Stacher-Priehse… - Anticancer …, 2022 - ar.iiarjournals.org
Background/Aim: The aim of the study was to identify predictors of long-term survival and
propose an improved risk stratification in patients with pulmonary germ-cell metastases …

The proteasome regulator PSME4 drives immune evasion and abrogates anti-tumor immunity in NSCLC

…, A Kacen, M Alon, AT Ręgo, E Stacher-Priehse… - bioRxiv, 2021 - biorxiv.org
Protein degradation by proteasomes is important for the immune response against tumors.
Antigens generated by the proteasome promote immune cell infiltration into tumors and …